First results of a randomized trial (APL91 trial) and other randomized or non-randomized studies have shown that ATRA followed by chemotherapy significantly increased event-free survival (EFS) and survival, and decreased the incidence of relapse by comparison to chemotherapy alone in newly diagnosed APL. We present here long-term follow-up of the APL91 trial. In this trial, 101 patients had been randomized between ATRA followed by three courses of daunorubicin-AraC chemotherapy (ATRA group) and the same chemotherapy alone (chemotherapy group). Results were reanalyzed 73 months after closing of patient entry. Updated results of APL 91 trial found a Kaplan-Meier estimate of EFS and relapse rate at 4 years of 63% and 31% in the ATRA group, as compared to 17% and 78% in the chemotherapy group (P = 10 −4 and relative risk 2.95, P = 10 −4 and relative risk 3.68, respectively). Kaplan-Meier survival at 4 years was 76% in the ATRA group and 49% in the chemotherapy group (P = 0.026, relative risk 2.7). In the chemotherapy group, seven of the 27 relapses occurred after 18 months, but no relapse was seen after 43 months. In the ATRA group, four of the 17 relapses occurred after 18 months, including two late relapses (at 58 and 74 months). In the chemotherapy group, 23 of the 25 patients who relapsed achieved a second CR with ATRA, and the Kaplan-Meier estimate of second relapse was 40% at 30 months. In the ATRA group, the 10 patients who relapsed and were retreated with ATRA achieved a second CR. In conclusion, long-term results of APL91 trial confirm the superiority of the combination of ATRA and chemotherapy over chemotherapy alone in newly diagnosed APL, and that ATRA should be incorporated in the front-line treatment of APL. Leukemia (2000) 14, 1371-1377.
Introduction
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) characterized by the morphology of blast cells (M3), 1,2 t(15;17) translocation, 3 which fuses the PML gene on chromosome 15 to the retinoic acid receptor (RAR) alpha gene on chromosome 17, 4, 5 and by a specific coagulopathy. 6, 7 Until the end of the 1980s, combination chemotherapy with anthracycline-cytosine arabinoside (Ara C) was the only treatment for APL, which gave complete remission (CR) in 65 to 80% of newly diagnosed cases. [8] [9] [10] [11] [12] Fifty to 65% of the patients who achieved CR subsequently relapsed. [8] [9] [10] [11] [12] All-trans retinoic acid (ATRA) can differentiate abnormal promyelocytes into mature granulocytes in APL in vitro and in vivo [13] [14] [15] [16] and can induce CR in 80% to 90% of newly diagnosed 13, [15] [16] [17] and first-relapsing APL. 18 Two randomized trials (including our APL91 trial and a US intergroup study) have shown that the combination of ATRA and chemotherapy improved event-free survival and survival in newly diagnosed APL by comparison with chemotherapy alone, mainly by reducing the incidence of relapse. 19, 20 Other non-randomized studies have also strongly suggested the beneficial effect of the addition of ATRA to chemotherapy in newly diagnosed APL. [21] [22] [23] [24] Follow-up was relatively short in all those studies, however, and the possibility that the addition of ATRA had only delayed some of the relapses could not be completely ruled out.
In the present report, based on long-term follow-up of the APL91 trial, we confirmed the survival benefit obtained with ATRA combined with chemotherapy over chemotherapy alone in newly diagnosed APL. We also analyzed the outcome of patients who relapsed after chemotherapy alone and ATRA combined with chemotherapy.
Patients and methods

Eligibility criteria
Between 1 March 1991 and 1 December 1992, 101 patients from 46 European centers with newly diagnosed APL were included in APL91 trial. This trial had been approved by ethical committees in all countries.
Inclusion criteria were: (1) diagnosis of APL, based on morphology criteria; 1,2 (2) age 65 years or less in APL91 trial; (3) informed consent. Diagnosis had to be subsequently confirmed by presence of t (15;17) or PML-RAR alpha gene rearrangement. In the absence of t (15;17) and if no analysis of the rearrangement could be made, review of initial marrow slides by an independent morphologist was mandatory.
Protocol design
Patients were randomized to receive chemotherapy alone (chemotherapy group) or ATRA followed by chemotherapy (ATRA group). In the chemotherapy group, patients received two successive courses of daunorubicin (DNR) 60 mg/m 2 /day for 3 days and Ara-C 200 mg/m 2 /day for 7 days (courses I and II). Those who achieved CR after course I received a final course of DNR 45 mg/m 2 /day for 3 days and Ara-C 1 g/m 2 every 12 h for 4 days (course III). Patients who achieved CR only after course II received two cycles of course III. Patients with resistant leukemia after courses I and II were considered as failures and were administered ATRA. In the ATRA group, patients received ATRA 45 mg/m 2 /day orally until CR, or for a maximum of 90 days. After CR achievement, they received the same three chemotherapy courses as in the chemotherapy group. Course I was however added to ATRA on day 1 of treatment if initial WBC were greater than 5 × 10 9 /l, and rapidly started if WBC rose above 6000/mm 3 , 10 000/mm 3 or 15 000/mm 3 by day 5, 10 and 15 of ATRA treatment, respectively, because from our experience patients were at risk of ATRA syndrome above those thresholds. 20 After relapse, treatment options were left to each center's decision.
End points
Event-free survival (EFS), calculated from the date of randomization, was the main endpoint. The CR rate, time to relapse calculated from CR achievement and overall survival, calculated from the date of randomization, were considered as secondary endpoints. Failures were classified as (1) early death: death during ATRA or chemotherapy, or during the period of aplasia following chemotherapy, without evidence of resistant leukemia; (2) resistant leukemia: absence of CR after courses I and II of chemotherapy, or after 90 days of treatment with ATRA (whether or not one chemotherapy course had been added). CR criteria included disappearance of abnormal promyelocytes on bone marrow aspirate and of significant coagulopathy, neutrophils Ͼ1500/mm 3 , platelets Ͼ100 000/ mm 3 and no transfusion requirement. In patients who relapsed, EFS and survival were also evaluated from relapse, and time to second relapse from the achievement of a second CR.
Statistical analysis
Analysis was made on an intention-to-treat basis, in patients with confirmed diagnosis of APL. Censored criteria were analyzed with the Kaplan-Meier estimate, 25 the life-time actuarial estimate, 26 the log-rank test 27 and the Cox's model 26 using 1 January 1999 as the reference date (fifth interim analysis). For each endpoint, treatment comparison was adjusted on a predetermined subset of prognostic factors [8] [9] [10] [11] [12] [13] using either logistic regression (CR achievement) or Cox's model (other endpoints): age, WBC count, platelet count, absolute number of circulating blasts, M3 subtype ('classical' M3 vs microgranular variant M3), presence of significant coagulopathy, and fibrinogen level. They were introduced as binary covariates after dichotomization according to median values. All tests were two-sided. The SAS software (SAS Institute, Cary, NC, USA) was used.
Results
Summary of preliminary results
One hundred and two patients were included. Diagnosis of APL was confirmed in 101 cases, by presence of t(15;17) in 75 cases, PML-RAR alpha rearrangement in seven cases and centralized review of the slides in 19 cases. The last patient eventually proved to have M2AML with t(8;21) and was excluded. In the ATRA group, 49 (91%) of the 54 patients included achieved CR and five (9%) had early death. Fourteen patients achieved CR with ATRA alone, and 35 with ATRA plus chemotherapy added due to WBC counts Ͼ5000/mm 3 at diagnosis, or to increasing WBC counts on ATRA treatment. In the chemotherapy group, 38 (81%) of the 47 patients included achieved CR, four (8%) had early death and five (10%) had leukemic resistance. The difference in CR rate was not significant (P = 0.25). In the ATRA group, the ATRA syndrome 19 occurred in 6% of the patients, but none of those cases was fatal. The first interim analysis, performed at the reference date of 1 December 1992, showed significantly higher EFS (P = 0.002) and lower estimate of relapse (P = 0.005) in the ATRA group than in the chemotherapy group. 19 The third interim analysis, performed at the reference date of 1 October 1994 also showed a significantly better survival in the ATRA group (P = 0.01). 28 
Results of the fifth interim analysis
This analysis was performed at the reference date of 1 January 1999, 73 months after closing the trial for entry. Five patients, including three in the ATRA group and two in the chemotherapy group, were lost to follow-up in CR, 65 to 80 months after inclusion. Two patients, one in the ATRA group and one in the chemotherapy group, were allografted in first CR, from a familial HLA-identical sibling. Kaplan-Meier estimate of relapse was 8% at 1 year and 31% at 4 years in the ATRA group, as compared to 30% and 78%, respectively, in the chemotherapy group (P = 10 −4 by the log rank test, relative risk: 3.68, 95% confidence interval 2.00-6.75; after adjustment on the seven predetermined prognostic parameters, P = 0.0001, relative risk: 3.49, 95% confidence interval 1.86-6.53) (Figure 1a ). In the ATRA group, 17 patients relapsed, after 7 to 74 months, including four relapses after 18 months (at 31, 33, 58 and 74 months, respectively). In the chemotherapy group, 27 patients relapsed, after 1 to 43 months, and five died in first CR. Seven of the relapses occurred after 18 months (at 21, 21, 22, 31, 35, 42 and 43 months, respectively). The estimated yearly hazard function ( Figure 1a) shows a greater than 50% reduction in relapse with ATRA for the first 3 years of follow-up. The high early relapse-hazard in the chemotherapy group tended to decrease after 2 years.
The Kaplan-Meier estimate of EFS was 83% at 1 year and 63% at 4 years in the ATRA group, as compared to 53% and 17%, respectively, in the chemotherapy group (P = 10 −4 by the log-rank test, relative risk: 3.37, 95% confidence interval 1.98-5.73; after adjustment on the seven prognostic parameters, P = 10 −4 , relative risk: 2.95, 95% confidence interval 1.70-5.11). The estimated yearly hazard function (Figure 1b) shows the large decrease in events with ATRA during the first 2 years and a low hazard rate from the third year.
In the ATRA group, 13 patients died, all from their disease. Kaplan-Meier estimate of overall survival was 91% at 1 year and 76% at 4 years. In the chemotherapy group, 25 patients died and all deaths were disease-related. Kaplan-Meier estimate of overall survival was 74% at 1 year and 49% at 4 years (P = 0.0026 by the two-sided log rank test, relative risk: 2.7, 95% confidence interval 1.38-5.28; after adjustment on the seven prognostic parameters, P = 0.026, relative risk: 2.24, 95% confidence interval 1.10-4.57). The estimated yearly hazard function (Figure 1c) demonstrates the early effect of ATRA on overall survival.
Results in patients with high WBC counts
Twenty-eight patients, including 16 in the ATRA group and 12 in the chemotherapy group, had WBC counts greater than 10 000/mm 3 at diagnosis. In those patients, Kaplan-Meier estimate of EFS at 4 years was 50% in the ATRA group, as compared to 15% in the chemotherapy group (RR = 2.62, P = 0.04); Kaplan-Meier estimate of relapse at 4 years was 43% in the ATRA group, as compared to 80% in the chemotherapy group (RR = 2.94, P = 0.048); Kaplan-Meier estimate of survival at 4 years was 69% in the ATRA group, as compared to 61% in the chemotherapy group (RR = 1.59, P = 0.45).
Prognostic factors in the ATRA group
None of the predetermined prognostic factors derived from previous studies were predictive for CR achievement. There was a non-significant trend for lower EFS and higher incidence of relapse in patients with WBC Ͼ10 000/mm 3 
, platelets
Leukemia Ͻ50 000/mm 3 and circulating blasts Ͼ500/mm 3 at inclusion. There was also a trend for shorter survival with the same factors and age Ͼ55 years (data not shown).
Outcome of relapses and of failures to achieve CR (Table 1)
In the ATRA group, seven of the 16 patients who relapsed were treated with chemotherapy and five of them achieved a second CR. Ten patients (including one of those who did not respond to chemotherapy) were retreated with ATRA (with addition of chemotherapy in four cases who developed high Table 1 Outcome of relapses in APL 91 trial WBC counts, according to the same thresholds as for induction treatment). All 10 patients achieved CR. Of the 15 patients who obtained a second CR, one was allografted with a familial donor: he was still in CR after 73+ months; five were autografted using bone marrow (three cases) or peripheral stem cells (two cases) harvested in second CR: one relapsed after 7 months, three remained in CR after 38+ to 40+ months and one developed MDS, without evidence of APL relapse, 62 months after the autograft; nine patients received consolidation chemotherapy: five relapsed, one died in second CR, during aplasia after a consolidation course, and three remained in second CR after 25+, 77+ and 77+ months. The second CR was longer than the first CR in six cases, including the allografted patient, three autografted patients and two patients consolidated with chemotherapy alone; it was shorter than the first CR in six cases, and no comparison could be made in three cases (two were still in second CR, but with a follow-up shorter than the first CR, and one rapidly died in second CR). The Kaplan-Meier estimate of second relapse, in patients who achieved a second CR, was 57% at 30 months. Median Kaplan-Meier EFS and survival after a first relapse were 11 months and not achieved, respectively (Figure 2 ). In the chemotherapy group, 25 of the 27 patients who relapsed were treated with ATRA (with or without chemotherapy) and 23 achieved CR; two relapses were retreated with chemotherapy alone and CR was achieved in both patients; one of them relapsed after 4 months and one remained in CR, 34 months after autologous BMT. Of the 23 patients who achieved a second CR with ATRA, five received a familial donor allograft: four remained in second CR after 53+ to 63+ months; six received an autologous bone marrow (four cases) or stem cell (two cases) transplantation: four remained in second CR after 36+ to 68+ months; 13 patients received consolidation chemotherapy: six remained in second CR after 39+ to 75+ months. In the 23 patients who achieved a second CR with ATRA, the second CR was longer than the first in 15 patients (including three allografted patients, three autografted patients and nine patients consolidated with chemotherapy alone), shorter in four patients and not comparable in four patients. The Kaplan-Meier estimate of second relapse, in patients who achieved a second CR, was 40% at 30 months. Median Kaplan-Meier EFS and survival after a first relapse were 27 months and 47 months, respectively (Figure 2) .
Of the five patients who in the chemotherapy group failed to achieve CR after two courses of chemotherapy, one achieved CR with additional chemotherapy. He was then allografted but died from the procedure. The four other patients achieved CR with ATRA. One was then allografted and he remained in CR after 71+ months; three were consolidated by chemotherapy and two of them relapsed after 6 and 9 months, whereas the remaining patient was still in CR after 80+ months.
Discussion
Prolonged follow-up in the present APL91 trial, confirmed the EFS and survival advantage obtained by the combination of ATRA and chemotherapy over chemotherapy alone in newly diagnosed APL, mainly through reduction in the incidence of relapse. Indeed, a greater than 50% reduction of the risk of relapse during the first 2 years, without any increase after 2 years, was seen with ATRA. Of note however was the occurrence of two late relapses, after 58 and 74 months, in the ATRA group, which constituted 12% (two of 17) of the relapses in that group. By contrast, the last relapse occurred at 43 months in the chemotherapy group, confirming the rare occurrence of relapses beyond 4 years after chemotherapy alone in APL. [8] [9] [10] [11] [12] A large number of studies of APL treated with ATRA and chemotherapy has now been published, but their follow-up is currently not sufficient to confirm whether or not this combination treatment is associated with an increased risk of late relapses. [20] [21] [22] [23] [24] 29 Data on long-term follow-up of those studies is therefore awaited.
Although the combination of ATRA and chemotherapy has improved the outcome of APL, some patients still have early death and others still relapse. Long-term results of the ATRA group of the APL91 trial failed to show significant prognostic factors of relapse, EFS and survival, but the number of patients was probably too small to draw a definite conclusion. Larger studies (including our APL93 trial) have shown that several pretreatment factors, including WBC count, platelet count, and possibly the type of bcr rearrangement, significantly influence the relapse risk. [30] [31] [32] In addition, monitoring of minimal residual disease (MRD) by reverse transcriptase polymerase chain reaction (RT-PCR) is a reliable tool for predicting outcome in APL after CR achievement. [33] [34] [35] In the present report, as expected, almost all the patients who relapsed after treatment with chemotherapy alone achieved a second CR with ATRA. Importantly, more than half (15 of 23) of those patients had a second CR longer than the first CR, and many of them were probably cured of their disease. Long-term salvage after a first relapse occurred not only in patients who were allografted, but also in patients who were autografted or consolidated with intensive chemotherapy. Also of note is that two of the five patients who failed to achieve a first CR with chemotherapy were durably salvaged by ATRA followed by intensification treatment. In spite of this relatively high incidence of durable salvage, however, longterm survival remained significantly lower in the chemotherapy group than in the ATRA group. This clearly confirmed that ATRA should be incorporated in the front-line treatment of newly diagnosed APL.
In the ATRA group, all the patients who relapsed and were retreated with ATRA achieved a second CR. Four of them also received chemotherapy due to high or increasing WBC counts, which could have explained their response. However, the remaining six patients achieved second CR with ATRA alone. Response to ATRA in patients who relapse after firstline treatment with ATRA is controversial. In vitro studies have demonstrated that progressive resistance to ATRA occurs in APL cells exposed to this treatment, due to increased catabolism of the drug. 36 In those studies, resistance decreased after discontinuation of the drug, and cells regained sensitivity to ATRA 3 to 4 months after its discontinuation. 37 In vivo, we also observed that relapses occurring within 6 months of ATRA discontinuation showed no or limited response to ATRA, whereas later relapses responded better to ATRA. 36 The fact that, in the ATRA group of the APL91 trial, all relapses occurred at least 7 months after ATRA discontinuation possibly explained the favorable response we observed with this drug in relapsing patients.
Finally, contrary to a recent MRC study, 29 patients with initial WBC counts greater than 10 000/mm 3 also appeared to benefit from the combination of ATRA and chemotherapy, as EFS and estimate of relapse were significantly better in the ATRA group, in spite of the low number of patients (16 in the ATRA group and 12 in the chemotherapy group). This did not translate into survival differences, but survival at 4 years was 61% in the 12 patients treated with chemotherapy alone, ie Leukemia higher than for the whole chemotherapy group (49%), possibly due to the small sample.
In conclusion, long-term results of the APL91 trial clearly confirm the superiority in terms of survival of the combination of ATRA and chemotherapy over chemotherapy alone in APL. Efforts should now aim at further reducing the incidence of early death and of relapse. Results of the recently closed European APL93 trial, for instance, strongly suggest that the concomitant use of ATRA and chemotherapy for induction (rather than ATRA followed by chemotherapy) and maintenance treatment combining low-dose chemotherapy and intermittent ATRA can reduce the relapse rate, especially in patients presenting with high WBC counts. 30 A place for arsenic trioxide in first-line treatment, especially in patients at high risk of relapse, will also have to be determined. 38, 39 It has also been suggested recently that when combined with ATRA, chemotherapy with an anthracycline alone was less toxic and probably as efficient as classical anthracycline-Ara-C regimens. 40 Finally, several reports have shown the feasibility of close monitoring in case of minimal residual disease by RT-PCT in APL, in order to start early treatment of 'molecular' relapse, before the occurrence of clinical relapse. 41 
